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Inflammatory Bowel Disease  
Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal 
tract with two distinct phenotypes: Crohn’s disease (CD) and ulcerative colitis (UC). 
Approximately 10% of all patients with IBD manifestations in the colon have overlapping 
features of both phenotypes and are categorized as ‘IBD unclassified’ (IBDU).(1)  
CD has a classic triad of presenting symptoms: abdominal pain, weight loss and diarrhoea. In 
contrast, weight loss is relatively rare as presenting symptom in patients with UC, in which 
rectal bleeding tends to be more prominent at the time of diagnosis. Clinical presentation of 
either of the two types of IBD varies according to the location, severity and chronicity of 
inflammation.(2) About 10% of all new patients with IBD are younger than 19 years of age at 
the time of diagnosis.(3) Compared to adults, children are more likely to present with 
extensive disease and to be at greater risk of complications.(2)  
Strategies for diagnosing IBD, alleviating symptoms and improving well-being have been 
subjects of intensive research. Nevertheless, conclusive answers have yet to be provided 
regarding important research questions concerning the management of paediatric IBD (see 





Table 1: Knowledge gaps concerning paediatric IBD  
Diagnostics  
Appropriate triage for patients with gastrointestinal complaints for endoscopic evaluation  
Reliable monitoring of disease activity in ambulatory patients 
Treatment 
Understanding the effect of enteral nutrition on inflammation (and predicting 
success/failure) 
Comparison between novel and currently available medication for children: long-term 
safety and efficacy  
Use of genetic profiling to develop precision medicine 
Effect of altering the gut microbiome with anti/pro/prebiotics 
Education of patients 
Optimizing drug adherence 
Achieving treatment self-competence and autonomy in adolescents 
Improving quality of life 
Supporting psychological growth 
Physical and psychological impact of lifelong therapy 
Quantification and characterisation of fatigue in IBD 
Identifying factors associated with fatigue 
 
Inflammatory bowel disease is a chronic illness that is frequently characterized by periods of 
exacerbation and remission, and that often follows a progressive course. Unpredictable 
flares, frequent hospitalizations and chronic medication use affect psychosocial functioning 
and limit social activities.(4) Early recognition of IBD can reduce the inflammation in an early 
Chapter 1  General introduction
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phase of the disease, what could subsequently alter the course of the disease and prevent 
long-term complications.  
In the absence of full curative treatment, the current ultimate goal of paediatric IBD care is to 
minimize the burden of disease for patients. This thesis focuses on the triage of children with 
abdominal complaints with regard to endoscopic evaluation, as well as on recognizing fatigue 
in IBD patients. In the first part of this thesis, we investigate strategies to improve the 
diagnostic pathway to identify children with gastrointestinal complaints due to IBD for whom 
endoscopic evaluation is indicated. In the second part, we address quality-of-life issues 
following the diagnosis of IBD and, more specifically, persistent fatigue in clinically inactive or 
mild/moderate IBD.  
Part I - Triage for endoscopy 
Endoscopy of the upper and lower gastrointestinal tract with biopsies is the reference 
standard for diagnosing IBD.(1) At the same time however, many patients with 
gastrointestinal complaints do not appear to have IBD. Since endoscopy is an invasive 
diagnostic procedure with the possibility of harmful complications, only patients with the 
highest risk of inflammatory disorders should be exposed to endoscopy. For general 
paediatricians who see many patients with gastrointestinal complaints (e.g. recurrent 
abdominal pain, diarrhoea), it may be a challenge to decide which child should be referred 
for endoscopy. A non-invasive test could enhance the process of triage for children with 
regard to referral for endoscopy. This triage test could be very helpful if it would be reliable 
in preventing children at low risk of IBD from undergoing endoscopy.  
As stated above, IBD is characterized by chronic inflammation of parts of the intestine. For 
this reason, blood and urine markers have traditionally been assessed as indicators of 
intestinal inflammation in patients suspected of having IBD.(5) In current practice, C-reactive 
protein (CRP) and the erythrocyte sedimentation rate (ESR) continue to be the most 
frequently used blood markers for inflammation. Despite the common use of such blood 
markers, their specificities and sensitivities for IBD are low, making them less suitable for 
decision making regarding which patients with gastrointestinal complaints should or should 
not be referred for endoscopy.(6) Substances that are excreted in urine (e.g. neopterin, 
13 
 
leukotriene E-4 and prostaglandine E metabolite) have also been investigated as markers of 
inflammation. To date, however, none of these markers has been validated for clinical use.(5)  
Faecal markers 
Before a biomarker can be safely used as a clinical triage test, its discriminatory power must 
be defined upon the intended patient population and in a specific clinical setting within the 
current diagnostic pathway. This is because the sensitivity and specificity of a test can vary 
according to the patient population and clinical setting.(7) 
 
Figure 1 l Roles of tests and positions in existing diagnostic pathways. Figure adapted from (7) 
Given that the inflammation in IBD is an intestinal process, it is logical that faecal parameters 
have also been suggested as being valuable for the assessment of intestinal inflammation.  In 
practice, faecal markers have indeed become very popular for assessing the presence of 
inflammation in the bowel. During mucosal inflammation, various substances are actively 
released or passively leaked into the intestinal lumen, and they are subsequently excreted in 
the stool. An overview of the faecal parameters that have been evaluated is presented in 
Table 2.(8, 9)  
  
Chapter 1  General introduction
13
146809-Vijver_BNW.indd   12 16-10-2020   09:54
12 
 
phase of the disease, what could subsequently alter the course of the disease and prevent 
long-term complications.  
In the absence of full curative treatment, the current ultimate goal of paediatric IBD care is to 
minimize the burden of disease for patients. This thesis focuses on the triage of children with 
abdominal complaints with regard to endoscopic evaluation, as well as on recognizing fatigue 
in IBD patients. In the first part of this thesis, we investigate strategies to improve the 
diagnostic pathway to identify children with gastrointestinal complaints due to IBD for whom 
endoscopic evaluation is indicated. In the second part, we address quality-of-life issues 
following the diagnosis of IBD and, more specifically, persistent fatigue in clinically inactive or 
mild/moderate IBD.  
Part I - Triage for endoscopy 
Endoscopy of the upper and lower gastrointestinal tract with biopsies is the reference 
standard for diagnosing IBD.(1) At the same time however, many patients with 
gastrointestinal complaints do not appear to have IBD. Since endoscopy is an invasive 
diagnostic procedure with the possibility of harmful complications, only patients with the 
highest risk of inflammatory disorders should be exposed to endoscopy. For general 
paediatricians who see many patients with gastrointestinal complaints (e.g. recurrent 
abdominal pain, diarrhoea), it may be a challenge to decide which child should be referred 
for endoscopy. A non-invasive test could enhance the process of triage for children with 
regard to referral for endoscopy. This triage test could be very helpful if it would be reliable 
in preventing children at low risk of IBD from undergoing endoscopy.  
As stated above, IBD is characterized by chronic inflammation of parts of the intestine. For 
this reason, blood and urine markers have traditionally been assessed as indicators of 
intestinal inflammation in patients suspected of having IBD.(5) In current practice, C-reactive 
protein (CRP) and the erythrocyte sedimentation rate (ESR) continue to be the most 
frequently used blood markers for inflammation. Despite the common use of such blood 
markers, their specificities and sensitivities for IBD are low, making them less suitable for 
decision making regarding which patients with gastrointestinal complaints should or should 
not be referred for endoscopy.(6) Substances that are excreted in urine (e.g. neopterin, 
13 
 
leukotriene E-4 and prostaglandine E metabolite) have also been investigated as markers of 
inflammation. To date, however, none of these markers has been validated for clinical use.(5)  
Faecal markers 
Before a biomarker can be safely used as a clinical triage test, its discriminatory power must 
be defined upon the intended patient population and in a specific clinical setting within the 
current diagnostic pathway. This is because the sensitivity and specificity of a test can vary 
according to the patient population and clinical setting.(7) 
 
Figure 1 l Roles of tests and positions in existing diagnostic pathways. Figure adapted from (7) 
Given that the inflammation in IBD is an intestinal process, it is logical that faecal parameters 
have also been suggested as being valuable for the assessment of intestinal inflammation.  In 
practice, faecal markers have indeed become very popular for assessing the presence of 
inflammation in the bowel. During mucosal inflammation, various substances are actively 
released or passively leaked into the intestinal lumen, and they are subsequently excreted in 
the stool. An overview of the faecal parameters that have been evaluated is presented in 
Table 2.(8, 9)  
  
Chapter 1  General introduction
13
146809-Vijver_BNW.indd   13 16-10-2020   09:54
14 
 
Table 2: Faecal markers of inflammation (8, 9) 
Faecal marker Molecular function/cellular source Number of articles in 
paediatric literature 
(1990 - June 2019) 
Lysozyme Released with degranulation of 
Paneth cells, macrophages and 
granulomas 
20 
Polymorphonuclear elastase Released with degranulation of 
polymorfonuclear granulocytes; 
plays a role in the first-line host 
defence  
43 
Myeloperoxidase Cytotoxic lysosomal protein 
released with degranulation of 
activated neutrophils  
47 
Metalloproteinase-9 Protein involved in neutrophil 
migration process, released by a 
variety of cell types, including 
activated neutrophils  
3 
Neopterin Synthesized by activated 
macrophages; serves as marker of 
cellular immune-system activator  
23 
Lactoferrin Cytoplasmic iron binding 
glycoprotein secreted by 
neutrophils and mucosal epithelial 
cells  
21 
Calprotectin (S100A8/S100A9) Cytoplasmic calcium binding protein 
released by neutrophils, monocytes 
and epithelial cells  
154 
 
All substances listed in Table 2 are found in abundance in the faeces of patients with active 
IBD, and concentrations are significantly lower in patients in remission.(5, 10) Calprotectin 
has been studied more extensively in children than any other faecal marker, and this 




Evaluating the accuracy of the calprotectin stool test 
In 2010, we wrote a diagnostic meta-analysis (11) on the applicability of calprotectin as a 
triage test. All the articles included in that meta-analysis were based on the fully paired design 
that is typical of Phase II diagnostic accuracy studies. In these studies, a group of patients 
suspected of having IBD underwent faecal calprotectin testing followed by the reference 
standard: endoscopy. These studies estimated the diagnostic accuracy of faecal calprotectin 
under ideal experimental conditions. 
In the next phase, a triage test (e.g. faecal calprotectin) needs to be used as means of triage 
before performing the existing diagnostic test (i.e. endoscopy), and only patients with positive 
results on the triage test will continue along the diagnostic pathway (see Figure 1). In ‘Phase 
III’ diagnostic accuracy studies, accordingly, not all suspected patients would need to undergo 
the reference standard.(12) To date, no Phase III diagnostic accuracy studies have been 
performed with regard to the potential value of faecal calprotectin. Therefore, we set 
ourselves to test the accuracy of faecal calprotectin with respect to the identification of 
patients with gastrointestinal complaints that should be referred for endoscopy because of 
IBD.  
In Chapter 2 we assess the role of faecal calprotectin as a triage test in the diagnostic work-
up of children with gastrointestinal complaints (such as chronic abdominal pain, diarrhoea) in 
a Phase III diagnostic accuracy study. All children will have a faecal calprotectin test, but not 
all suspected patients will undergo endoscopy. The decision to expose a patient to endoscopy 
will be based on the physicians’ clinical gut feeling. They are blinded to the FC result and 
consequently cannot take this result into account. 
Faecal calprotectin is not the only marker for intestinal inflammation. Another candidate 
marker that could aid in differentiating IBD from IBS is Calgranulin-C (S100A12). Calgranulin-
C is released almost exclusively by activated granulocytes, and has hardly been investigated 
as a marker of intestinal inflammation.(13) In previous case control studies, calgranulin-C 
showed diagnostic promise, exhibiting better specificity for intestinal inflammation relative 
to calprotectin.(14-16) In Chapter 3, we investigate the use of calgranulin-C to predict IBD in 
children and teenagers with chronic abdominal pain and diarrhoea, and we compare its 
accuracy to that of the calprotectin stool test.  
Chapter 1  General introduction
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Chapter 4 describes a further refinement of the formulated diagnostic test strategy of chapter 
2, based on repeating the study in a separate and large validation cohort. We use an optimized 
cut off for calprotectin in combination with blood markers, and modify the inclusion criteria 
of the study cohort.  
 
Part II - Quality of life beyond clinical remission: Fatigue in paediatric IBD 
Treatment goals in IBD have changed considerably over the years. In the past, treatment was 
limited to controlling exacerbation, and it was aimed at alleviating clinical symptoms. The 
introduction of biological agents as anti-inflammatory therapy marked the beginning of a new 
era. Mucosal healing became the primary goal of treatment. The use of these agents have 
decreased rates of surgery and hospitalization.(17) In current practice, the focus of IBD 
treatment is typically on anti-inflammatory agents and therapies that modulate the immune 
system. However, many symptoms may not be directly caused by active inflammation, but 
may involve other mechanisms, including disease-associated symptom experience and 
psychological processes.(18) Moreover, the increasing recognition of, and appreciation for, 
the importance of health-related quality-of-life has spurred the use of such patient-important 
outcomes in clinical trials. 
Quality of life in IBD 
The World Health Organization defines quality of life as ‘an individual's perception of their 
position in life, in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns’.(19) In IBD, stress and 
psychological health are likely to play an important role in symptom experience. For this 
reason, an exclusive focus on anti-inflammatory therapies is not expected to fully serve the 
needs of the patient. One important symptom that is frequently reported by IBD patients is 
fatigue.  
Fatigue  
Fatigue refers to a subjectively overwhelming sense of tiredness, lack of energy and a feeling 
of exhaustion that decreases an individual’s capacity for physical and mental activity.(20) It is 
17 
 
a common, independent and nonspecific symptom that has been identified in numerous 
chronic health conditions in childhood, including IBD.(21)  
Fatigue can be a major source of disablement in patients with a chronic disease, and it is often 
reported as being amongst the most severe and distressing symptoms.(22) Fatigue affects 
physical, emotional, cognitive and social functioning, and it has an impact on the quality of 
life. Despite its importance, researchers have rarely included and quantified fatigue in 
assessments of symptom severity or outcomes of chronic diseases in which it is observed, 
including chronic obstructive pulmonary disease, cystic fibrosis, chronic renal disease, cancer 
and heart failure.(22) 
The quantification of fatigue poses several challenges, due to the lack of a consensus 
framework, vague terminology and a multidimensional nature of symptoms. Although 
subjective methods (e.g. self-reported or parent-reported surveys)(23, 24) are commonly 
used, they can be distorted by response and recall bias. More objective methods (e.g. 
polysomnography and performance tests)(25-27) are expensive and time-consuming, and the 
prevalence of fatigue varies by age group. For example, it is common in infancy, early 
childhood and late adolescence, while being less frequently observed in mid-childhood, and 
it is more common in girls than it is in boys.(26) Such variations in fatigue amongst healthy 
children makes it difficult to quantify fatigue in patients.  
Fatigue is determined by a variety of factors. In adult studies, active inflammation, depression 
and other factors are implied in fatigue. A recent review on fatigue in IBD patients classifies 
factors into two categories: modifiable and non-modifiable.(28) The modifiable factors 
include physical factors (e.g. disease activity, anaemia, physical functioning and fitness), as 
well as psychosocial factors (e.g. anxiety, depression and self-directed personality). Non-
modifiable factors include disease duration, gender and extra-intestinal manifestations. All 
studies in the review describe adult patients, and it is unclear whether a similar classification 
would apply to children with IBD. For this reason, we performed a systematic review of the 
existing literature aimed at exploring the prevalence of fatigue in paediatric IBD and 
identifying elements that contribute to fatigue (Chapter 5). Several studies have suggested 
that disease activity, anaemia and physical functioning affect the experience of fatigue.(24, 
29-31) 
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In Chapter 6, we evaluate the effect of anaemia, subclinical inflammation and physical fitness 
on the sense of fatigue. For that, we conducted a cross-sectional observational study in 
children and adolescents with IBD. This study is based on validated questionnaires for fatigue 
and quality of life, endurance testing, blood testing and stool analysis to delineate fatigue in 
IBD. The study is intended to assess the extent to which the severity of fatigue is correlated 
with disease-related factors and biochemical parameters.  
In Chapter 7, we discuss the implications of our different studies for clinical practice, a few 
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In Chapter 6, we evaluate the effect of anaemia, subclinical inflammation and physical fitness 
on the sense of fatigue. For that, we conducted a cross-sectional observational study in 
children and adolescents with IBD. This study is based on validated questionnaires for fatigue 
and quality of life, endurance testing, blood testing and stool analysis to delineate fatigue in 
IBD. The study is intended to assess the extent to which the severity of fatigue is correlated 
with disease-related factors and biochemical parameters.  
In Chapter 7, we discuss the implications of our different studies for clinical practice, a few 
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